Skip to main content

Peer Review reports

From: Neoadjuvant plus adjuvant or only adjuvant nab-paclitaxel plus gemcitabine for resectable pancreatic cancer - the NEONAX trial (AIO-PAK-0313), a prospective, randomized, controlled, phase II study of the AIO pancreatic cancer group

Original Submission
11 Aug 2017 Submitted Original manuscript
21 Sep 2017 Author responded Author comments - Thomas Ettrich
Resubmission - Version 2
21 Sep 2017 Submitted Manuscript version 2
18 Aug 2018 Author responded Author comments - Thomas Ettrich
5 Jun 2018 Reviewed Reviewer Report - Jean Luc Van Laethem
26 Jun 2018 Reviewed Reviewer Report - Somnath Mukherjee
Resubmission - Version 3
18 Aug 2018 Submitted Manuscript version 3
Publishing
4 Dec 2018 Editorially accepted
29 Dec 2018 Article published 10.1186/s12885-018-5183-y

You can find further information about peer review here.

Back to article page
\